The combination of intermittent treatment of vemurafenib and DM-1 compound for melanoma therapies (2015)
- Authors:
- Autor USP: ENGLER, SILVYA STUCHI MARIA - FCF
- Unidade: FCF
- Assunto: MELANOMA (TERAPIA)
- Language: Inglês
- Imprenta:
- Source:
- Título: Brazilian Journal of Pharmaceutical Sciences
- ISSN: 1984-8250
- Volume/Número/Paginação/Ano: v. 51, suppl. 1, p. 4 res. FCF003, 2015
- Conference titles: Pharmaceutical Science and Technology Meeting of the Faculty of Pharmaceutical Sciences, University of São Paulo
-
ABNT
OLIVEIRA, Érica Aparecida de et al. The combination of intermittent treatment of vemurafenib and DM-1 compound for melanoma therapies. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 13 jan. 2026. , 2015 -
APA
Oliveira, É. A. de, Souza, G. F. de, Suárez, J. A. Q., & Maria-Engler, S. S. (2015). The combination of intermittent treatment of vemurafenib and DM-1 compound for melanoma therapies. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. -
NLM
Oliveira ÉA de, Souza GF de, Suárez JAQ, Maria-Engler SS. The combination of intermittent treatment of vemurafenib and DM-1 compound for melanoma therapies. Brazilian Journal of Pharmaceutical Sciences. 2015 ; 51 4 res. FCF003.[citado 2026 jan. 13 ] -
Vancouver
Oliveira ÉA de, Souza GF de, Suárez JAQ, Maria-Engler SS. The combination of intermittent treatment of vemurafenib and DM-1 compound for melanoma therapies. Brazilian Journal of Pharmaceutical Sciences. 2015 ; 51 4 res. FCF003.[citado 2026 jan. 13 ] - Processo invasor do câncer cervical uterino: análise das metaloproteinases -2, -9, -14, TIMP-2 e do gene supressor de tumor RECK
- Organotypic models in drug development
- Evaluation of the expression of matrix metalloproteinase type 9 in cervicovaginal smears: a cytlogical study
- RECK is required for migration and invasiveness in melanoma after vemurafenib treatment
- Epithelial mesenchymal transition as an alternative pathway in vemurafenib and vemurafenib/trametinib chemoresistant melanoma
- Novel kojic acid derivatives ACT on melanogenesis and skin age-related enzymes
- Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma
- Evaluation of antimetastatic activity in vemurafenib resistant melanoma cell lines after DM-1 treatment
- Apoptosis expression in vemurafenib-resistant melanoma cells induced by curcumin analog DM-1
- RECK-tumor suppressor gene is overexpressed in vermurafenib-resistant human melanoma cells
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
